Mukka Proteins Ltd - 544135 - Intimation Regarding Change Of Corporate Identification Number ('CIN') And Company Status Of Mukka Proteins Limited ('The Company')
Please find attached herewith the intimation regarding change of CIN and Company Status of the Company. Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Plese find enclosed herewith copies of Newspaper Advertisements confirming completion of dispatch of Postal Ballot Notice to the shareholders. Mukka Proteins Ltd - 544135 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith the Postal Ballot Notice dated 14th May 2024 along with explanatory statement. Mukka Proteins Ltd - 544135 - Newspaper Advertisement Pursuant To Regulation 47 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
We are hereby enclosing copies of Newspaper Advertisement of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2024. Q4FY24 Quarterly & FY24 Annual Result Announced for Mukka Proteins Ltd.
Food Products company Mukka Proteins announced Q4FY24 & FY24 results: PAT for Q4 FY24, increased by 141.53% to Rs 29.15 crore from 12.07 crore in Q3FY24 (QoQ comparison) and increased by 32.99% in Q4FY24 from Rs 21.92 crore in Q4FY23 (YoY comparison) For the entire FY24, PAT increased by 56.35% to Rs 74.31 crore, from Rs 47.52 crore in FY23 On a QoQ basis, the EBITDA margins increased by 177.47%, to 14.38% in Q4FY24 from 5.18% in Q3FY24, indicating 920 bps improvement in the margins EBIDTA has improved by 37.77% to Rs 36.92 crore in Q4FY24 from Rs 26.80 crore in Q3FY24 PAT % as a % of Revenue has improved by 386.44%, to 11.36% in Q4FY24 from 2.33% in Q3FY24 and has improved by 117.96% compared to Q4FY23. On this occasion, Mohammed Haris, MD and CEO, Mukka Proteins said "We are extremely proud of the strong operational performance of the company in Q4FY24. The improvement in the margins clearly indicates that the management is focused on improving the profitability going forward as well. The use of IPO proceeds in the working capital requirements has boarded extremely well with the plans visualized by the management of the company. The sector promises to witness strong growth momentum going further in FY25 and in recent times the support from the Government through various schemes like Pradhan Mantri Matsya Sampada Yojana (PMMSY), Fisheries and Aquaculture Infrastructure Development Fund, Blue revolution 2.0 will only boost the prospects of the industry going forward. Our aim will be to surpass the industry growth and ensure that all our stakeholders including investors are extremely happy with the company’s performance”. Result PDF Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
We are enclosing herewith the Monitoring Agency Report dated May 14, 2024, issued by ICRA Limited for the quarter ended March 31, 2024. Mukka Proteins Ltd - 544135 - Statement Of Deviation(S) Or Variation(S) Of Funds Raised Through Initial Public Offer (''IPO'') For The Quarter Ended March 31, 2024
Please find enclosed herewith the statement of deviation(s) or variation(s) in utilization of funds raised through IPO for the quarter ended March 31, 2024. Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation of Press Release Mukka Proteins Ltd - 544135 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March 2024.
Audited financial results for the quarter and year ended 31st March 2024. Mukka Proteins Ltd - 544135 - Audited Financial Results For The Quarter And Year Ended 31St March 2024.
Audited financial results for the quarter and year ended 31st March 2024.